109 results about "Cell Maintenance" patented technology

The invention discloses a method for producing animal rabies viruses and animal rabies vaccines on a large scale. By using a bioreactor, the animal rabies viruses and the animal rabies vaccines are produced by a cell micro-carrier suspension culturing system on a large scale by the following steps of: inoculating cells for preparing the vaccine into a carrier tank containing culture solution and micro-carriers to attach the cells to the micro-carriers; growing the cells on the micro-carriers until the concentration of culture solution is 5 to 20 times the inoculation concentration under a proper culturing environment; preparing virus suspension from the rabies virus to adsorb the virus suspension to the cells; replacing cell maintenance culture solution to culture the virus under the proper culturing environment; continuously culturing for 3 to 5 days and harvesting the virus solution for the first time, wherein the solution replacement ratio is 50 percent by using a semi-continuous process; continuously culturing for 9 to 11 days and harvesting and replacing the solution once every 24 hours; and mixing the harvested virus solution and the virus solution of the bioreactor, repeatedly performing freeze-thawing twice at the constant temperature of -20 DEG C, inactivating, purifying and adding adjuvants to prepare the rabies vaccine. The method has the advantages of large production scale, high single-batch yield and relatively low production cost.

Handover (HO) statistics and handover issue events which are due to non-mobility causes are not included in the statistics fed into mobility robustness optimization (MRO). The non-mobility causes may include, e.g., load balancing, retracting users to prepare for cell maintenance or restart / reconfiguration and cell outage including compensation means. Radio link failure (RLF), handover failure (HOF), and handover oscillations (HOosc) that are due to non-mobility cause are excluded from the statistics upon which mobility robustness optimization is based. Non-mobility causes are also differentiated from mobility causes when reporting key performance indicators to an operator.

This invention relates to methods for rationally designing cell culture media for use in cell cultures, e.g., cell cultures employed in polypeptide production; cell culture media designed with the disclosed methods; methods of producing a polypeptide of interest, e.g., an antibody, using such media; polypeptides produced using the methods and media disclosed herein; and pharmaceuticals compositions containing such polypeptides. The rationally designed media contain a concentration of an amino acid that is calculated for use in cell mass, a concentration of the amino acid that is calculated for use in cell maintenance, and a concentration of the amino acid that is calculated for incorporation into the polypeptide of interest.

The invention discloses a method for preparing virus of porcine reproductive and respiratory syndrome on a large scale. In the method, the virus of the porcine reproductive and respiratory syndrome is prepared in a cell microcarrier suspension culture system by a bioreactor. The method comprises the following steps of: inoculating host cells for preparing the virus to a carrier tank containing culture solution and a microcarrier, and mixing the cells and the microcarrier uniformly to ensure that the cells are attached to the microcarrier; providing sufficient nutrients and appropriate gas environment for the cells under the appropriate culture environment to ensure that the cells are grown until the cells are in an amount which are 10 to 20 times of the inoculation concentration on the microcarrier; preparing virus suspension from the virus of the porcine reproductive and respiratory syndrome by using cell maintenance culture solution to ensure that the suspension is adsorbed to the cells; culturing the virus under the appropriate culture environment; culturing continuously for 2 to 3 days to obtain virus solution; and after the virus solution passes inspection, performing freeze thawing on the virus solution twice at the temperature of -20 DEG C, and inactivating and purifying to prepare an inactivated vaccine of the porcine reproductive and respiratory syndrome or adding a freeze-drying protective agent for freeze drying to prepare a live vaccine of the porcine reproductive and respiratory syndrome. The method has large production scale, high yield of single batch and low production cost.

A method and apparatus for maintaining the cells of a fuel cell stack are disclosed. The apparatus includes a fuel cell maintenance device including means for imposing a low impedance across at least one cell of a fuel cell stack, e.g., a switch, and a pulse generator. The pulse generator is capable of pulsing a cathode of the at least one cell of through the low impedance imposing means, e.g., when the switch is closed. The method transparently maintains the cells of a fuel cell stack, and includes sequentially pulsing the cathodes of a plurality of cells in a fuel cell stack, and maintaining a consistent number of the cells providing power to a load of the fuel cell stack while sequentially pulsing the cathodes of the cell.

The invention relates to a method for separating and extracting stem cells from a placenta, umbilical cord or adipose tissue, which comprises the following process steps: firstly mixing the placenta, umbilical cord or adipose tissue and a cell maintenance fluid according to the proportion by weight of 2.5-4:1, putting the mixture into a tissue crushing barrel, adding collagenase after crushing, uniformly mixing, hatching at the temperature of 37 DEG C, filtering, adding a precipitator, sucking a supernatant fluid after settling, centrifuging, removing the supernatant fluid, adding concentrated cells into a liquid of diatrizoate sodium-ficoll 400#, then centrifuging, collecting 10-15 ml of intermediate cell layer, washing with the cell maintenance fluid, counting the collected cells, and providing the cells for clinical use when the cell survival ratio is more than or equal to 95 percent. The invention not only realizes the separation and the extraction of all stem cells from the placenta, umbilical cord or adipose tissue, but also realizes industrialized production, and enables doctors to conveniently, safely and canonically obtain the adult stem cells in clinic and use the adult stem cells for treating the diseases of patients as using medicaments, thereby solving the bottleneck problem of difficult obtainment of adult stem cells in clinic and popularizing a cell treatment technology.